Illumina Inc ILMN

NAS: ILMN | ISIN: US4523271090   14/04/2026
130,32 USD (+2,65%)
(+2,65%)   14/04/2026

14 april 2026 · Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease · Persbericht

9 april 2026 · Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 · Persbericht

2 april 2026 · Illumina Announces Changes to Board of Directors · Persbericht

18 maart 2026 · Illumina and Labcorp expand collaboration to broaden access to precision oncology testing · Persbericht

16 maart 2026 · Illumina advances preventive genomics through strategic consortium with Veritas Genetics · Persbericht

5 maart 2026 · Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering · Persbericht

27 februari 2026 · Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida · Persbericht

25 februari 2026 · Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics · Persbericht

24 februari 2026 · Illumina launches TruPath Genome, setting a new standard in genomic insight · Persbericht

23 februari 2026 · Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility · Persbericht

17 februari 2026 · Illumina To Webcast Upcoming Investor Conference · Persbericht

5 februari 2026 · Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 · Persbericht

3 februari 2026 · Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally · Persbericht

30 januari 2026 · Illumina completes acquisition of SomaLogic · Persbericht

20 januari 2026 · Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology · Persbericht

13 januari 2026 · Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery · Persbericht

13 januari 2026 · Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 · Persbericht

12 januari 2026 · Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 · Persbericht

8 januari 2026 · Illumina Appoints Dr. Eric Green as Chief Medical Officer · Persbericht

6 januari 2026 · Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis · Persbericht

Mijn selecties